Global Difficult-to-Express Proteins Market - 2023-2030

Global Difficult-to-Express Proteins Market - 2023-2030

Market Overview

The global difficult-to-express proteins market reached US$ 4,007.6 million in 2022 and is projected to reach up to US$ 9,052.1 million by 2030. The difficult-to-express proteins market is expected to exhibit a CAGR of 11.0% during the forecast period (2023-2030). Key strategy acquisitions drive the difficult-to-express proteins market growth.

For instance, the acquisition of BioLegend, a top global supplier of life science antibodies and reagents, by PerkinElmer, Inc., a company dedicated to innovation for a healthier society, has been finalized. The acquisition cost was about US$ 5.25 billion. The largest acquisition in PerkinElmer's history will allow the company to further develop its life science business in high-growth industries like cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing.

The pinpointing of DNA coding series retained in the genome of numerous organisms associated with employing high throughput techniques has fueled the domain of recombinant protein production. In the past few years, the demand for biological compounds has grown and appears to hold a long run on the market. One of the considerably favored expression systems is established on Escherichia coli cells, which apart from being cost-effective, counts on an extensive preference for aids.

Nevertheless, a substantial portion of the genes of interest are not efficiently expressed in this design, or the expressed proteins accumulated within forms lumps or lack the expected biological action, being eventually dumped. Thus, such proteins require a specialized expression system, which is boosting the difficult-to-express proteins market growth.

Market Dynamics

The increasing demand for protein biologics is driving the difficult-to-express proteins market growth.

Most chronic diseases such as cancer, autoimmune diseases, and other serious diseases are treated using biologics. These biologics include vaccines, blood and blood components, and recombinant therapeutic proteins. Therefore, the rising cases of the mentioned chronic diseases among others are fueling the demand for biologics, thereby boosting the global difficult-to-express proteins market growth.

For instance, several mAbs, such as tocilizumab and sotrovimab, and the co-administration of bamlanivimab and etesevimab, had received EUA for COVID-19 treatment (mild to moderated) and evusheld (co-package of tixagevimab with cilgavimab) was authorized as a prophylactic for the prevention of the infection. Several of these drugs were to receive drug approvals from the FDA by 2022.

The technological advancements in the market provide the market players with growth opportunities

With growing interest in the heterologous production of proteins like antibodies, growth factors, nanobodies, and high-quality protein food ingredients, microfluidics is one of the most significant and cutting-edge techniques used in studies and research on protein expression. There is a rising need for effective production hosts. The outcomes demonstrated the effectiveness of DBM screening as a powerful tool for improving cell factories for the production and secretion of heterologous proteins.

Moreover, a cutting-edge technology called the Microfluidic Antibody Capture (MAC) chip is employed to assess the degree of protein expression and phosphorylation at the single-cell level. Microfluidics technology advancements have offered reliable solutions for the analysis and assessment of tumorous and non-tumorous cells, presenting the market with lucrative growth opportunities in the upcoming years.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a minimal impact on the global difficult-to-express proteins market, owing to the absence of key market players in this region. However, the impact of the import and export of raw materials, products, and devices is anticipated to have little influence over the global difficult-to-express proteins market over the forecast period.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. The recession has led to a decrease in research investments, which has negatively impacted the market growth in the past few years.

Artificial Intelligence Impact Analysis

According to an article sourced from the University of Washington School of Medicine/UW Medicine published in February 2023, scientists have utilized machine learning to construct brand-new enzymes, which are proteins that boost chemical reactions. The research team developed deep-learning, artificial intelligence algorithms that constructed light-emitting enzymes called luciferases. Laboratory testing proved that the new enzymes can identify distinct chemicals and radiate light with remarkable efficiency. Such developments in protein research with AI are expected to positively impact the global difficult-to-express protein market in the upcoming years.

Segment Analysis

The global difficult-to-express proteins market is segmented based on proteins, technology, applications, and region.

The cell-free protein synthesis segment is estimated to hold a majority of the difficult-to-express proteins market share during the forecast period.

The cell-free protein synthesis segment was valued at US$ 1,460.8 million in 2022, holding about 36.4% of the total difficult-to-express protein market share and is estimated to grow throughout the forecast period. The advantages of cell-free protein synthesis technology and increasing research activities are expected to boost segment growth during the forecast period.

For instance, in November 2022, multiple gene expressions in cell-free protein synthesis (CFPS) systems for reconstructing bacteriophages and metabolic pathways were done in Korea. Because of its open design, CFPS is ideal for designing novel viruses (or virus-like particles (VLPs)) or synthetic pathways with great liberty. CFPS can rush up the design-build-test process of synthetic biology by bypassing cell culture per procedure. CFPS would be additionally automation-friendly in bio-foundry form for the exact cause, which could additionally quicken up research.

Geographical Analysis

Europe is estimated to hold the second-largest share of the global difficult-to-express proteins market during the forecast period.

Europe is estimated to have a considerable market share of about 25.2% owing to the increased investment from government and non-government organizations. For example, Transine Therapeutics, a UK biotech startup researching a novel class of therapeutic RNAs, raised £4.6M (USD 5.8 million) in additional seed funding in May 2022. The financing was led by new investor Epidarex Capital, with a current investment, the Dementia Discovery Fund, also participating (DDF).

Competitive Landscape

The major global players in the market include Reaction Biology (Cobepa), LifeSensors Inc., Lucigen(LGC Group), BioLegend, Inc.(PerkinElmer Inc.), OriGene Technologies, Inc., R&D Systems, Enzo Life Sciences, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., and Merck KGaA, among others.

Why Purchase the Report?
• To visualize the global difficult-to-express proteins market segmentation based on product, application, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of difficult-to-express proteins market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global difficult-to-express proteins market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies